← Back to Clinical Trials
Recruiting NCT06217029

NCT06217029 Magnetic Resonance Imaging Study on Young and Middle-aged Patients With Cervical Spondylotic Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06217029
Status Recruiting
Phase
Sponsor First Affiliated Hospital Xi'an Jiaotong University
Condition Neck Pain
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2024-01-06
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type OBSERVATIONAL
Interventions
physiotherapy and maxillary traction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2024-01-06 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cervical and shoulder pain in young adults is commonly caused by intervertebral disc degeneration, bulge or herniation. Disc degeneration includes the synthetic and degradative imbalance of myxoid matrix, degeneration of annulus collagen, and decrease of water content in nucleus pulposus. A few patients with cervical degeneration had moderate to severe pain, but there are no obvious abnormalities in the shape and signal of the disc with routine MRI, which may be related to the early discal degeneration. In most cases, the pain could be relieved by non-surgical treatment due to mild decreased proteoglycan and slight abnormality of water diffusion, but these changes cannot be clearly demonstrated by routine MRI. Therefore, it is necessary to rely on sensitive MRI techniques to reflect the abnormal microstructure in the nucleus pulposus and annulus fibrosus, so as to assist the early detection of the main reason in patients with neck and shoulder pain and the evaluation of the efficacy of treatment.

Eligibility Criteria

Inclusion Criteria: 1. Neck and shoulder pain, with or without upper limb pain and numbness; 2. Disease duration longer than 2 months 3. Visual analogue score (VAS) ≥ 3 4. Cervical MRI showing cervical disc degeneration, bulge, protrusion, etc. 5. Patients will undergo non-surgical treatment (maxillary occipital traction, massage, etc.) Exclusion Criteria: 1. Severe trauma and surgery in neck and shoulder region. 2. X-ray or CT showing the severe cervical spine hyperplasia, infection (suppurative, tuberculous), neoplasm (various primary and secondary tumors), rheumatic (rheumatoid arthritis, ankylosing spondylitis), and nuclei pulposus calcification. 3. Cervical MRI revealed organic lesions such as inflammation of the spinal cord, tumors, syringomyelia, etc. 4. Chronic pain in other regions.

Contact & Investigator

Central Contact

Yuan Wang, M.D.

✉ wangyuan8003@126.com

📞 +8613324598144

Principal Investigator

Ming Zhang, M.D.

STUDY DIRECTOR

First Affiliated Hospital Xi'an Jiaotong University

Frequently Asked Questions

Who can join the NCT06217029 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Neck Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06217029 currently recruiting?

Yes, NCT06217029 is actively recruiting participants. Contact the research team at wangyuan8003@126.com for enrollment information.

Where is the NCT06217029 trial being conducted?

This trial is being conducted at Xi'an, China.

Who is sponsoring the NCT06217029 clinical trial?

NCT06217029 is sponsored by First Affiliated Hospital Xi'an Jiaotong University. The principal investigator is Ming Zhang, M.D. at First Affiliated Hospital Xi'an Jiaotong University. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology